6 versus 12 months of adjuvant trastuzumab for HER2 positive breast cancer (PERSEPHONE): definitive 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Submitting institution
-
University of Exeter
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 5608
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(19)30650-6
- Title of journal
- The Lancet
- Article number
- -
- First page
- 2599
- Volume
- 393(10191)
- Issue
- 10191
- ISSN
- 0140-6736
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
https://ars.els-cdn.com/content/image/1-s2.0-S0140673619306506-mmc1.pdf
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
30
- Research group(s)
-
C - Health Service Research
- Citation count
- 81
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author, CH, made a substantial contribution to: the conception and design of the study; and to the analysis and interpretation of study data. CH helped draft the output. CH led the health economics work stream following move of the lead health economist to Canada early in the project.
- Non-English
- No
- English abstract
- -